Biohaven Total Assets 2016-2022 | BHVN

Biohaven total assets from 2016 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Biohaven Annual Total Assets
(Millions of US $)
2021 $1,077
2020 $687
2019 $344
2018 $290
2017 $147
2016 $27
2015 $2
Biohaven Quarterly Total Assets
(Millions of US $)
2022-09-30 $136
2022-06-30 $1,386
2022-03-31 $1,372
2021-12-31 $142
2021-09-30 $1,131
2021-06-30 $846
2021-03-31 $1,003
2020-12-31 $687
2020-09-30 $782
2020-06-30 $424
2020-03-31 $533
2019-12-31 $0
2019-09-30 $439
2019-06-30 $491
2019-03-31 $245
2018-12-31 $290
2018-09-30 $195
2018-06-30 $239
2018-03-31 $126
2017-12-31 $147
2017-09-30 $185
2017-06-30 $214
2017-03-31 $60
2016-12-31 $27
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.240B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00